Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma.
The prognostic significance of S100A as potential biomarker for breast cancer was reported; however, this finding has recently been challenged. Here, the aim was to assess whether S100A4 could also be a prognostic biomarker of lung cancer. A specific high-titer anti-S100A4 monoclonal antibody was developed. The utility and specificity of this antibody was validated by immunostaining experiments. The antibody was tested against a newly developed high-density tissue microarray including 400 lung cancer tissues to examine the clinico-pathological and prognostic significance of S100A4 in lung cancer. The staining of S100A4 was significantly associated with patients' poor prognosis in lung squamous cell carcinoma but not lung adenocarcinoma. S100A4 seems to be a prognostic biomarker of lung squamous cell carcinoma (5-year survival rate of 38.5% versus 7.4%, p<0.01), but not of adenocarcinoma.